{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:52:37Z","timestamp":1790268757793,"version":"4.1.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["ARS01_00876"],"award-info":[{"award-number":["ARS01_00876"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>In this narrative review, we summarize the current knowledge on RNA-based therapies used in rare and ultrarare disorders and congenital diseases in which the kidneys may be involved. In these therapies, RNA molecules are packaged into delivery vehicles to reach the desired target. We describe only drugs that have been approved or are under review for approval by the US Food and Drug Administration and\/or the European Medicines Agency. We describe the potential therapeutic role of microRNA (miRNA) in Alport syndrome, polycystic kidney disease and renal cell carcinoma. Notably, large randomized clinical studies are required before these drugs can be introduced into clinical practice. The therapeutic effects of short interfering RNA molecules have been tested and evaluated in patients with various congenital or acquired diseases, such as primary hyperoxaluria, hereditary transthyretin amyloidosis, acute kidney injury after cardiovascular intervention or kidney transplantation (i.e. delayed graft function), and in individuals affected by hypercholesterolemia. In addition, synthetic antisense oligonucleotides have proven effective in patients with moderate or severe hypercholesterolemia who developed statin side effects, such as myalgia or rhabdomyolysis, and in individuals with amyloidosis. These new therapeutic approaches need to be validated through global clinical trials in which large patient samples can be enrolled. Nonetheless, some of these promising new approaches are currently undergoing evaluation for the treatment of common diseases, such as hypertension and diabetes, which are the main causes of chronic kidney disease.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf214","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:27:36Z","timestamp":1752240456000},"source":"Crossref","is-referenced-by-count":7,"title":["RNA therapeutics in kidney diseases: prospects and current status"],"prefix":"10.1093","volume":"18","author":[{"given":"Francesco Paolo","family":"Schena","sequence":"first","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d Department of Emergency and Organ Transplantation, , Bari ,","place":["Italy"]},{"name":"Schena Foundation , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pasculli","sequence":"additional","affiliation":[{"name":"Schena Foundation , Bari ,","place":["Italy"]},{"name":"University of Bari \u201cAldo Moro\u201d Department of Interdisciplinary Medicine, , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2025080103165803700_bib1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol Mol Biol Rev"},{"key":"2025080103165803700_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1298-9_1","article-title":"RNA interference: story and mechanisms","volume":"2282","author":"Sioud","year":"2021","journal-title":"Methods Mol Biol"},{"key":"2025080103165803700_bib3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"2025080103165803700_bib4","doi-asserted-by":"publisher","first-page":"5848046","DOI":"10.1155\/2018\/5848046","article-title":"The challenges and opportunities in the clinical application of noncoding RNAs: the road map for miRNAs and piRNAs in cancer diagnostics and prognostics","volume":"2018","author":"Krishnan","year":"2018","journal-title":"Int J Genomics"},{"key":"2025080103165803700_bib5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nature04917","article-title":"A germline-specific class of small RNAs binds mammalian Piwi proteins","volume":"442","author":"Girard","year":"2006","journal-title":"Nature"},{"key":"2025080103165803700_bib6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature07756","article-title":"Small RNAs in transcriptional gene silencing and genome defence","volume":"457","author":"Moazed","year":"2009","journal-title":"Nature"},{"key":"2025080103165803700_bib7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.1102514","article-title":"Crystal structure of Argonaute and its implications for RISC slicer activity","volume":"305","author":"Song","year":"2004","journal-title":"Science"},{"key":"2025080103165803700_bib8","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1126\/science.1088060","article-title":"A microRNA as a translational repressor of APETALA2 in Arabidopsis flower development","volume":"303","author":"Chen","year":"2004","journal-title":"Science"},{"key":"2025080103165803700_bib9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1126\/science.1091903","article-title":"MicroRNAs modulate hematopoietic lineage differentiation","volume":"303","author":"Chen","year":"2004","journal-title":"Science"},{"key":"2025080103165803700_bib10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0092-8674(03)00231-9","article-title":"bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila","volume":"113","author":"Brennecke","year":"2003","journal-title":"Cell"},{"key":"2025080103165803700_bib11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/jcp.25854","article-title":"Interplay between miRNAs and human diseases","volume":"233","author":"Paul","year":"2018","journal-title":"J Cell Physiol"},{"key":"2025080103165803700_bib12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat Rev Genet"},{"key":"2025080103165803700_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-60761-863-8_15","article-title":"The guideline of the design and validation of MiRNA mimics","volume":"676","author":"Wang","year":"2011","journal-title":"Methods Mol Biol"},{"key":"2025080103165803700_bib14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025080103165803700_bib15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2025080103165803700_bib16"},{"key":"2025080103165803700_bib17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","article-title":"A randomized controlled clinical trial testing effects of Lademirsen on kidney function decline in adults with Alport syndrome","volume":"19","author":"Gale","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025080103165803700_bib18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1124\/dmd.123.001446","article-title":"Pharmacokinetics and absorption, distribution, metabolism and excretion of RGLS4326 in mouse and monkey, an anti-miR-17 oligonucleotide for the treatment of polycystic kidney disease","volume":"51","author":"Kamel","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"2025080103165803700_bib19","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"2025080103165803700_bib20","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"2025080103165803700_bib21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest New Drugs"},{"key":"2025080103165803700_bib22","doi-asserted-by":"publisher","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"2025080103165803700_bib23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025080103165803700_bib24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025080103165803700_bib25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","article-title":"Therapeutic efficacy of nanoparticles and routes of administration","volume":"23","author":"Chenthamara","year":"2019","journal-title":"Biomater Res"},{"key":"2025080103165803700_bib26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"2025080103165803700_bib27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"2025080103165803700_bib28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib29","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/acs.bioconjchem.0c00268","article-title":"Investigational therapies for primary hyperoxaluria","volume":"31","author":"Kletzmayr","year":"2020","journal-title":"Bioconjug Chem"},{"key":"2025080103165803700_bib30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJMc2312941","article-title":"Lumasiran, isolated kidney transplantation, and continued vigilance","volume":"390","author":"Bacchetta","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2024.02.1439","article-title":"Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3","volume":"9","author":"Groothoff","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025080103165803700_bib32","doi-asserted-by":"crossref","first-page":"sfae383","DOI":"10.1093\/ckj\/sfae383","article-title":"The efficacy and safety of RNA interference for the treatment of primary hyperoxaluria: a systematic review and meta-analysis","author":"Yu","year":"2025","journal-title":"Clin Kidney J"},{"key":"2025080103165803700_bib33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"2025080103165803700_bib34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonzalez-Duarte","year":"2020","journal-title":"J Neurol"},{"key":"2025080103165803700_bib35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/ckj\/sfac157","article-title":"Reply to \u2018Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?","volume":"16","author":"Solignac","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025080103165803700_bib36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.acvdsp.2022.10.056","article-title":"HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"15","author":"Pavia","year":"2023","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"2025080103165803700_bib37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","article-title":"Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study","volume":"144","author":"Thielmann","year":"2021","journal-title":"Circulation"},{"key":"2025080103165803700_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00007890-201407151-00467","article-title":"Treatment with QPI-1002, a short interfering (SI) RNA for the prophylaxis of delayed graft function.: abstract# 2967","volume":"98","author":"Peddi","year":"2014","journal-title":"Transplantation"},{"key":"2025080103165803700_bib40","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2025080103165803700_bib42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.amjcard.2020.05.024","article-title":"A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran","volume":"128","author":"Asbeutah","year":"2020","journal-title":"Am J Cardiol"},{"key":"2025080103165803700_bib43","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025080103165803700_bib44","first-page":"100127","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero","year":"2022","journal-title":"Am Heart J Plus"},{"key":"2025080103165803700_bib45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jtcvs.2023.05.028","article-title":"Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting","volume":"167","author":"Deo","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025080103165803700_bib46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes","volume":"18","author":"Chambergo-Michilot","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"2025080103165803700_bib47","first-page":"82","article-title":"The effect of mipomersen in the management of patients with familial hypercholesterolemia: a systematic review and meta-analysis of clinical trials","volume":"8","author":"Astaneh","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025080103165803700_bib48","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"2025080103165803700_bib49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"2025080103165803700_bib50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib51","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2022.08.018","article-title":"Focal segmental glomerulosclerosis complicating therapy with inotersen, an antisense oligonucleotide inhibitor: a case report","volume":"81","author":"Law","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025080103165803700_bib52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MNH.0000000000000816","article-title":"Treatment potential in APOL1-associated nephropathy","volume":"31","author":"Friedman","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025080103165803700_bib53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-pathol-051220-092001","article-title":"Pathogenesis of focal segmental glomerulosclerosis and related disorders","volume":"20","author":"Altintas","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"2025080103165803700_bib54","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of Cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025080103165803700_bib55","doi-asserted-by":"publisher","first-page":"152876","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"issue":"Suppl 1","key":"2025080103165803700_bib56","doi-asserted-by":"publisher","first-page":"gfae069","DOI":"10.1093\/ndt\/gfae069.1327","article-title":"# 388 IONIS-FB-LRx, an antisense oligonucleotide to complement factor B for treatment of IgA nephropathy","volume":"39","author":"Hladunewich","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025080103165803700_bib57","first-page":"SA","article-title":"IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement Factor B, in IgA nephropathy","author":"Barratt","year":"2023","journal-title":"American Society of Nephrology (ASN) Kidney Week Philadelphia, PA, USA"},{"key":"2025080103165803700_bib58","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"2025080103165803700_bib59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40200-024-01405-7","article-title":"Small interfering RNA (siRNA) as a potential gene silencing strategy for diabetes and associated complications: challenges and future perspectives","volume":"23","author":"Waghode","year":"2024","journal-title":"J Diabetes Metab Disord"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf214\/63727883\/sfaf214.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/8\/sfaf214\/63727883\/sfaf214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/8\/sfaf214\/63727883\/sfaf214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:17:05Z","timestamp":1754032625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf214\/8196607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf214","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,11]]},"article-number":"sfaf214"}}